Apalutamide and Overall Survival in Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

Apalutamide and Overall Survival in Prostate Cancer

DOI Full Paper Access

277

Citations

20

References

2020

Year

Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura,

European Urology

Abstract

With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic castration-resistant prostate cancer.

References

	Year	Citations
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Howard I. Scher, Susan Halabi, Ian F. Tannock, Journal of Clinical Oncology	2008	2.2K
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer Kim N., Neeraj Agarwal, Anders Bjartell, New England Journal of Medicine	2019	1.4K
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Charles J. Ryan, Matthew R. Smith, Karim Fizazi, The Lancet Oncology UrologyOncologyPrednisone Versus PlaceboAbiraterone AcetateClinical Trials	2015	1.3K
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Matthew R. Smith, Fred Saad, Simon Chowdhury, New England Journal of Medicine	2018	1.3K
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer Maha Hussain, Karim Fizazi, Fred Saad, New England Journal of Medicine	2018	1K
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, New England Journal of Medicine	2019	890
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment Nicola J. Clegg, John Wongvipat, James D. Joseph, Cancer Research	2012	646
Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer Matthew R. Smith, Fairooz F. Kabbinavar, Fred Saad, Journal of Clinical Oncology	2005	493
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer Cora N. Sternberg, Karim Fizazi, Fred Saad, New England Journal of Medicine	2020	404
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302) Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, European Urology UrologyOncologyAbiraterone AcetateMedicinePharmacotherapy	2014	271

Page 1